Icosavax, Inc. (ICVX)
Feb 20, 2024 - ICVX was delisted (reason: acquired by AstraZeneca)
15.31
0.00 (0.00%)
Inactive · Last trade price on Feb 16, 2024

Company Description

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology.

Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine.

The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target.

Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington.

Icosavax, Inc.
Icosavax logo
CountryUnited States
Founded2017
IPO DateJul 29, 2021
IndustryBiotechnology
SectorHealthcare
Employees60
CEOAdam K. Simpson

Contact Details

Address:
1930 Boren Ave., Suite 1000
Seattle, Washington 98101
Phone(206) 737-0085
Websiteicosavax.com

Stock Details

Ticker SymbolICVX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$15.00
CIK Code0001786255
CUSIP Number45114M109
ISIN NumberUS45114M1099
SIC Code2836

Key Executives

NamePosition
Adam K. SimpsonPresident, Chief Executive Officer, Co-Founder and Director
Niranjan Kanesa-thasan M.D.Chief Medical Officer
Dr. Cassia Cearley Ph.D.Treasurer and Chief Business Officer
Neil King Ph.D.Chair of Scientific Advisory Board and Co-Founder
Dr. David Baker M.D., Ph.D.Co-founder and Member of Scientific Advisory Board
Thomas Joseph Russo C.F.A.Chief Financial Officer
Jennifer RaymondSenior Vice President of Technical Operations
Elizabeth BekirogluGeneral Counsel and Corporate Secretary
Lori StewartSenior Vice President of People and Culture
Dr. Ami Shah Brown MPH, Ph.D.Senior Vice President of Regulatory Affairs

Latest SEC Filings

DateTypeTitle
Feb 21, 2024SC TO-T/AFiling
Feb 20, 2024EFFECTNotice of Effectiveness
Feb 20, 202425-NSEFiling
Feb 20, 2024S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Feb 20, 2024POS AMPost-Effective amendments for registration statement
Feb 20, 20248-KCurrent Report
Feb 20, 2024SC 14D9/AFiling
Feb 20, 2024SC TO-T/AFiling
Feb 15, 2024SC TO-T/AFiling
Feb 15, 2024SC 14D9/AFiling